A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

ClinicalTrials.gov ID: NCT06343805

Public ClinicalTrials.gov record NCT06343805. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II Janus Kinase 2 (JAK2) inhibitor, LY5830966, in participants with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.

Study identification

NCT ID: NCT06343805
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Enrollment: 256 participants

Conditions and interventions

Conditions

Primary Myelofibrosis

Interventions

LY5830966 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 3, 2024 (Actual)
Primary completion: Jun 2027 (Estimated)
Completion: Dec 2028 (Estimated)
Last update posted: Oct 9, 2026

2024 – 2028

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
Stanford Cancer Institute	Palo Alto	California	94304	Recruiting
Moffitt Cancer Cancer Center	Tampa	Florida	33612	Recruiting
University of Kansas Medical Center	Kansas City	Kansas	66160	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02115	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering	New York	New York	10021	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
University of Cincinnati	Cincinnati	Ohio	45221	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06343805, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 9, 2026 · Synced Nov 6, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06343805 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →